Genenta Science S.p.A (GNTA) Prepaid Assets (2020 - 2025)
Genenta Science S.p.A (GNTA) posted Prepaid Assets of $2.1 million for Q4 2025, down 43.42% sequentially from $3.8 million in Q2 2025, and up 9.96% YoY from $1.9 million in Q4 2024.
Genenta Science S.p.A (GNTA) Prepaid Assets (2020 - 2025) Analysis & Trends
Genenta Science S.p.A has reported Prepaid Assets for 6 years, with the latest figure at $2.1 million in Q4 2025.
- Quarterly Prepaid Assets rose 9.96% year-over-year to $2.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $2.1 million (up 9.96% YoY) and the FY2025 annual result came in at $2.1 million, up 9.96% from the prior year.
- Prepaid Assets declined to $2.1 million in Q4 2025 per GNTA's latest filing, from $3.8 million in the prior quarter.
- Over five years, Prepaid Assets peaked at $3.8 million in Q2 2025 and troughed at $217784.9 in Q2 2023.
- A 5-year average of $2.1 million and a median of $2.0 million in 2022 frame the typical range for Prepaid Assets.
- The sharpest annual moves came in 2023 and 2024: Prepaid Assets tumbled 92.54% in 2023, then surged 722.46% in 2024.
- Over 5 years, Prepaid Assets stood at $1.7 million in 2021, then advanced by 13.11% to $2.0 million in 2022, then surged by 35.79% to $2.7 million in 2023, then decreased by 27.4% to $1.9 million in 2024, then rose by 9.96% to $2.1 million in 2025.
- According to Business Quant data, Prepaid Assets over the past three periods registered $2.1 million, $3.8 million, and $1.9 million for Q4 2025, Q2 2025, and Q4 2024 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Genenta Science S.p.A | 25.03 Mn | -34.07 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2.13 Mn |
| Jun 30, 2025 | 3.77 Mn |
| Dec 31, 2024 | 1.94 Mn |
| Jun 30, 2024 | 1.79 Mn |
| Dec 31, 2023 | 2.67 Mn |
| Jun 30, 2023 | 217,784.88 |
| Dec 31, 2022 | 1.97 Mn |
| Jun 30, 2022 | 2.92 Mn |
| Dec 31, 2021 | 1.74 Mn |
| Dec 31, 2020 | 1.13 Mn |